AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 221 min read$ARGX

argenx Q3 revenue and profit rises (ARGX:NASDAQ)

argenx reported Q3 EPS of $7.80, up from $5.18 a year earlier, with product net sales rising 53% to $1.72B. The company expects combined R&D and SG&A expenses to total around $4B in 2026, including Forte Biosciences-related costs.

Original reporting
seekingalpha.com
Published Oct 22, 2026, 5:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 5:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ARGX
Bullish
high confidence
Mentioned
$ARGX
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ARGXBullishHigh
01

Why it matters

Earnings beat suggests positive momentum for the stock.

02

Market read

First report of strong Q3 earnings for a mid-cap biotech, likely to move the stock.

03

What to watch

Potential increased R&D spend of $4B in 2026 may pressure margins.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

argenx released its Q3 earnings via a press release.

Company-level read

Ticker impact

$ARGXBullishHigh confidence
Context

Q3 EPS $7.80 diluted and net sales $1.72B reported for the quarter.

Expected impact

upward pressure as the market prices in the earnings beat

Evidence & confidence

Revenue and EPS both significantly exceed prior year, indicating robust growth.

Market effects

Sector

Biotech sector may see broader uplift from strong earnings.

Regional

US biotech stocks could benefit.

Global

Limited to biotech investors.

Counterpoint

What could challenge this read

If guidance falls short of expectations, the rally could be short-lived.

Key entities

  • company
    argenx

    Biopharmaceutical company reporting Q3 results.

Read at source← All news

StoryArgenx posts Q3 2026 sales surge and announces Forte Biosciences acquisition

Also covered by

6 outlets

Related articles

OCT 22
$ARGXHighAI 8/10

Key facts: ARGX Q3 Sales $1.7B; FDA Priority Review for VYVGART Hytrulo

argenx (ARGX) reported Q3 2026 sales of $1.7B, up 54% YoY, with net profit of $506M. FDA granted priority review for VYVGART Hytrulo, with a PDUFA date set for February 2027. The company also announced positive Phase 3 results for VYVGART in IMNM and dermatomyositis, and plans to file an sBLA for IMNM by year-end. ARGX closed the Forte Biosciences deal, spending about $2.1B, and has cash of near $3.7B as of September 30, 2026.

tradingview.com2 min
OCT 22
$ARGXMed

Argenx says Vyvgart sales rose 54% in third quarter

Argenx reported a 54% increase in Vyvgart sales to $1.7B in Q3, treating generalized myasthenia gravis. Operating profit was $486M, below estimates. The company completed a $2.2B acquisition of Forte Biosciences, adding a drug for vitiligo and celiac disease. Operating margin declined to 28.2% due to acquisition costs, and R&D expenses are expected to reach $4B by 2026.

marketscreener.com2 min
OCT 22
$ARGXHighAI 8/10

argenx SE Reports Strong Q3 Earnings, Shares Trade Well Below GF

argenx SE (ARGX) reported Q3 2026 earnings per share of $7.80, up from $5.18 a year ago, with product sales growing 53% YoY to $1.72B. The company trades at $890.05, 44.3% below its GF Value of $1,597.83, indicating undervaluation. ARGX has a GF Score of 79, reflecting strong financial health and growth. Institutional investors show confidence, with eight gurus holding the stock.

gurufocus.com3 min